PT-141 (Bremelanotide) 10mg

Mechanism of Action PT-141:

is a non-selective agonist of melanocortin receptors, specifically targeting the MC3R and MC4R receptors in the brain's hypothalamus.

Neurological Trigger:

By activating these receptors, the peptide stimulates the release of dopamine, a neurotransmitter heavily involved in sexual motivation, reward, and pleasure.

Desire vs. Mechanics:

It addresses the "want" (libido) rather than just the "can" (physical blood flow), though it can indirectly support erections in men by triggering nitric oxide release.

Clinical Use and FDA Approval Approved Use:

Marketed under the brand name Vyleesi, it is FDA-approved for treating Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women.

Off-Label Use:

While not specifically FDA-approved for men, it is frequently used off-label for erectile dysfunction (ED), particularly in cases where psychological factors are involved or where patients do not respond to PDE5 inhibitors.

Dosage and Administration PT-141 is most commonly administered via subcutaneous injection into the abdomen or thigh, though intranasal sprays are also used in some settings.

Typical Dose:

Research often points to a standard dose of 1.75 mg.

Timing:

It is taken on an "as-needed" basis, typically 45 minutes to 2 hours before sexual activity.

Frequency:

Users are generally advised not to exceed one dose in 24 hours and no more than eight doses per month.

Comparison with PDE5 Inhibitors (Viagra/Cialis):

PT-141: Primary Target - Central Nervous System (Brain) Main Effect - Increases sexual desire and libido Stimulation - Can work without physical stimulation Synergy - Often stacked with PDE5s for a dual effect PDE5 Inhibitors: Primary Target - Vascular System (Blood Vessels) Main Effect - Increases blood flow to the genitals Stimulation - Requires sexual stimulation to work Synergy - Standard first-line therapy